Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508538 | 0.84 | EPHX1 (0.51) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL2200272 | 0.83 | EPHX1 (0.56) | EPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL6331846 | 0.82 | EPHX1 (0.50) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL4916180 | 0.81 | EPHX1 (0.57) | EPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL1357850 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL12582224 | 0.80 | RAB9A (0.51) | ALDH1A1SMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL27501559 | 0.79 | RAB9A (0.50) | ALDH1A1SMN1; SMN2LMNAL3MBTL1NPC1 | |
| SCHEMBL1357848 | 0.79 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL13020964 | 0.79 | EPHX1 (0.62) | EPHX1ALDH1A1SMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL793387 | 0.79 | EPHX1 (0.62) | EPHX1ALDH1A1SMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6345711-A | — | — | None | — | — | JP | disclosed |
| US-20170293225-A1 | PHOTOSENSITIVE RESIN COMPOSITION AND CURED PRODUCT THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-10-12 | — | — | US | disclosed |
| US-9377685-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9377685-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20130078572-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130078572-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20110172421-A1 | N-(alpha-AROMATIC GROUP-SUBSTITUTED-2-NITRO-4,5-DIALKOXYBENZYLOXYCARBONYL)AMINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | SHOWA DENKO K.K. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20090305437-A1 | FABRICATION OF INORGANIC MATERIALS USING TEMPLATES WITH LABILE LINKAGE | CAMBRIOS TECHNOLOGIES CORPORATION (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2007103539-A2 | FABRICATION OF INORGANIC MATERIALS USING TEMPLATES WITH LABILE LINKAGE | CAMBRIOS TECHNOLOGIES CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-6045977-A | COATING AN INTEGRATED CIRCUITS WITH A SOLUTION COMPRISING POLYANILINE AND AN ADDITIVE DISSOLVED IN A SOLVENT, THE ADDITIVE DISSOCIATES AND FORMS A POLYANILINE SALT | LUCENT TECHNOLOGIES INC. (US) | 2000-04-04 | — | — | US | disclosed |
| JP-H06345711-A | (((2-NITRO-4, 5-DIMETHOXYBENZYL) OXY)CARBONYL)CYCLOHEXYLAMINE AND METHOD FOR UTILIZING THE SAME | AIBAITSU KK | 1994-12-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172421-A1 | N-(alpha-AROMATIC GROUP-SUBSTITUTED-2-NITRO-4,5-DIALKOXYBENZYLOXYCARBONYL)AMINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | NME2, DAO, NMBR | EPHX1 1377/4885ALDH1A1 982/4885SMN1; SMN2 4414/4885 |
| US-20090305437-A1 | FABRICATION OF INORGANIC MATERIALS USING TEMPLATES WITH LABILE LINKAGE | ILK, ECPAS, STUB1 | EPHX1 2467/4885ALDH1A1 3671/4885SMN1; SMN2 2238/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | EPHX1 504/4885ALDH1A1 2036/4885SMN1; SMN2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.